Report #2856849

Received Sep 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: GA
Recovered: Unknown
Vaccinated: Feb 20, 2025
Onset: Feb 20, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	74NC9	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Inappropriate Schedule of Vaccine; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 74NC9, expiry date 13-NOV-2026) for prophylaxis. Previously administered products included Shingrix (received first dose on 17 Feb 2023 with lot 943GF). On 20-FEB-2025, the patient received the 2nd dose of Shingrix. On 20-FEB-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Inappropriate Schedule of Vaccine). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 12-AUG-2025 The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule.